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Observational dataObjective:We described the role of patient-related and clinical factors on age disparities in colon cancer survival
among patients aged 50–99 using New Zealand population-based cancer registry data linked to hospitalisation
data.
Method: We included 21,270 new colon cancer cases diagnosed between 1 January 2006 and 31 July 2017,
followed up to end 2019. We modelled the effect of age at diagnosis, sex, ethnicity, deprivation, comorbidity,
and emergency presentation on colon cancer survival by stage at diagnosis using flexible excess hazard regres-
sion models.
Results: The excess mortality in older patients was minimal for localised cancers, maximal during the first six
months for regional cancers, the first eighteen months for distant cancers, and over the three years for missing
stages. The age pattern of the excessmortality hazard varied according to sex for distant cancers, emergency pre-
sentation for regional and distant cancers, and comorbidity for cancer with missing stages. Ethnicity and depri-
vation did not influence age disparities in colon cancer survival.
Conclusion: Factors reflecting timeliness of cancer diagnosis most affected age-related disparities in colon cancer
survival, probably by impacting treatment strategy. Because of the high risk of poor outcomes related to treat-
ment in older patients, efforts made to improve earlier diagnosis in older patients are likely to help reduce age
disparities in colon cancer survival in New Zealand.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Older patients with colon cancer have poorer cancer survival than
younger patients [1]. The disadvantage in cancer survival in older adults
has even been widening [1], suggesting that they have not benefitted
from the improvements in cancer diagnosis and treatment at the same
magnitude as younger people. Previous work showed that low survival
in older patients with colon cancer was mainly explained by a high ex-
cess hazard in the first year after diagnosis [2].
Because of age-related physiological changes, comorbidity, and
polypharmacy, older patients have a higher risk of drug interaction,
and chemotherapy-related toxicity [3]. They are also more likely to
have comorbidities [4], cognitive impairment [5], to be depressed [6],International Classification of
s.
th, University of Otago, PO Box
ron).
. This is an open access article underand isolated with poor social support [7]. In addition, older patients
are seldom included in randomized clinical trials [8]. Physicians have,
therefore, to extrapolate from evidence based on younger patients to
adapt new treatment strategies to older patients. As a consequence,
older patients with cancer are likely to receive suboptimal treatment
[9]. Besides, they are more likely to be diagnosed with cancer after an
emergency presentation, and this has been associated with poor cancer
survival [10].
The magnitude of the age disparity in colon cancer survival varied
inconsistently by stage at diagnosis, sex, ethnicity, and socioeconomic
factors across studies [11]. While age is an important prognostic factor,
only a few population-based studies described the role of patient and
clinical factors on age disparities in colon cancer survival per se11.
In New Zealand, colon cancer was the second most common cancer
and the second biggest cause of cancer deaths in adults aged 70 years or
older in 2018 [12]. The most recent five-year net survival estimates for
colon cancer was 62% (95% confidence interval: 61%–63%), similar to
most western countries [1]. New Zealand has universal healthcare cov-
erage, with some co-payments for primary care but no cost at point ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patients' characteristics by age group.
Age categories (years) 50–64 65–74 75–84 85–99
Cases (%) 4212 (19.8) 6614 (31.1) 7371 (34.7) 3073 (14.4)
Male (%) 2193 (52.1) 3499 (52.9) 3458 (46.9) 1126 (36.6)
Ethnicity (%)
Māori 384 (9.1) 335 (5.1) 208 (2.8) 43 (1.4)
Non-Māori 3828 (90.9) 6279 (94.9) 7163 (97.2) 3030 (98.6)
Deprivation Index quintiles (%)
1 - Less deprived 831 (19.7) 1182 (17.9) 1133 (15.4) 463 (15.1)
2 782 (18.6) 1244 (18.8) 1353 (18.4) 553 (18.0)
3 873 (20.7) 1450 (21.9) 1673 (22.7) 700 (22.8)
4 946 (22.5) 1587 (24.0) 1882 (25.5) 816 (26.6)
5 - Most deprived 780 (18.5) 1151 (17.4) 1330 (18.0) 541 (17.6)
Stage at diagnosis (%)
Localised 1020 (24.2) 1712 (25.9) 1854 (25.2) 529 (17.2)
Regional 1782 (42.3) 3060 (46.3) 3261 (44.2) 1087 (35.4)
Distant 1115 (26.5) 1392 (21.0) 1405 (19.1) 619 (20.1)
Missing 295 (7.0) 450 (6.8) 851 (11.5) 838 (27.3)













1225 (29.1) 1746 (26.4) 2164 (29.4) 1176 (38.3)
IQR: Inter-quartile range.
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sion of surgical and oncology care.
Using New Zealand population-based cancer registry data linked to
hospitalisation data, we describe, for the first time, the contribution of
sex, ethnicity, deprivation, comorbidities, and emergency presentation
on age disparities in colon cancer survival.
2. Methods
The full description of method including the statistical analysis is in
Supplementary Methods. We included new colon cancer cases (ICD-
10 codes C18.0-C18.9) diagnosed between 1 January 2006 and 31 July
2017 from the New Zealand population-based cancer registry, that we
linked to hospitalisation data for thefive years before the cancer diagno-
sis, and to the outpatient dataset where all emergency admissions are
recorded. Rectal cancer cases (ICD10: C20), and all rectosigmoid cancer
cases (ICD10: C19)were excluded.We obtained the date of death for all
cancer cases dead by 31 December 2019 from the Ministry of Health.
We restricted our analyses to patients aged between 50 and 99 years
old at diagnosis with a first occurrence of colon cancer.
We categorised the extent of disease as given by the cancer registry
into Surveillance, Epidemiology and End Results (SEER) stage groups as
follows: Localised to the organ of origin or invasion of adjacent tissue or
organ into SEER localised stage; Regional lymphnodes involvement into
SEER regional stage; Distant into SEER distant stage; Not known into
missing stage [13].
We used the “all-sites” weighted C3 index that has been developed
from 42 conditions and validated using New Zealand cancer data to as-
sess comorbidity among patients with cancer using administrative
hospitalisation data [14]. In brief, a weight is assigned to each comorbid
condition. The weight corresponds to the parameter estimate (i.e., the
log hazard ratios) in the Cox regression model of noncancer death,
adjusting for age, site and stage. The index scores were calculated for
each patient by adding together all parameter estimates for all comor-
bid conditions recorded for that patient [14]. We defined emergency
presentation at diagnosis as a cancer diagnosis occurring in the 28
days following admission to an emergency department [15].
Sex and age at diagnosis were available for all cases within the can-
cer registry. We assessed the socio-economic deprivation at cancer di-
agnosis using the New Zealand Deprivation Index [16]. We could not
map domicile code to deprivation index for 36 patients, who were,
therefore, excluded from analyses.
Self-reported ethnicity, available in the cancer registry, originated
from the health records. We grouped patients into Māori and non-
Māori. The ethnicity was not available for 249 patients, who, were,
therefore, excluded from analyses.
2.1. Statistical Analysis
For each stage at diagnosis, we derived net survival from the estima-
tion of individual excess mortality hazard (EMH) using flexible excess
hazard regressionmodels. We created lifetables of mortality in the gen-
eral population from those obtained from Statistic New Zealand. We
censored all patientswhowere still alive beyondfive years after diagno-
sis formodel stability at the tails [17]. For each stage,wefirst defined the
functional form of the baseline hazard. Then, we selected the final
model using the strategy ofWynant and Abrahamowicz adapted for rel-
ative survival setting by Maringe et al. [18] We forced the lifetable var-
iables (i.e. sex, age, ethnicity, year at diagnosis) into the models. We
tested the non-linear effect of age at diagnosis, year of diagnosis and co-
morbidity score. For all covariates, we tested for time-dependent effects
and their interaction with age at diagnosis using the Likelihood
Ratio Test.
We performed data management using Stata (version 16.0;
StataCorp, 2019) and statistical analyses using R statistical software1045(version 3.4.0; R Development Core Team, 2017), in particular the
‘mexhaz’ package was used for flexible excess hazard modelling [19].
2.1.1. Ethics Approval
The University of Otago Human Ethics Committee (Health) ap-
proved the study (Ethics Committee reference number HD19/048).3. Results
Out of 2, 003 patients diagnosedwith colon cancer between January
2006 and July 2017, we included 21,270 patients aged 50–99 (median
age at diagnosis = 74, interquartile range 67–81; 51.7% females).
Table 1 presents the characteristics of the included patients by age at di-
agnosis, and Supplementary Table 1 by age at diagnosis and stage at di-
agnosis. While patients under 75 years old were mostly males, older
patients were mainly females. Non-Māori constituted the majority of
the newly diagnosed patients, and their percentage increased as the
age at diagnosis increased. Deprivation level was evenly distributed
across age groups. Overall, 24.0% of patients were diagnosedwith local-
ised cancer, 43.2% with regional cancer, 21.3% with distant cancer, and
11.4% had a missing stage. The percentage of missing stage increased
after the age of 75, and it was twice higher in the 85–99 age group
than in the 75–84 age group. The comorbidity score increased with
age, with over three quarters of patients aged over 85 who had a posi-
tive comorbidity score compared to half of patients aged 50–64. Overall,
29.7% of patients were diagnosedwith colon cancer after an emergency
presentation, and the percentage was the highest in the oldest age
group.
The one-, and three- year net survival estimates were, respectively,
98.1% (95% confidence interval: 97.6%–98.5%), and 95.8% (95.0%–
96.6%) in patients with localised stage, 91.4% (90.7%–92.0%), and
79.8% (78.8%–80.8%) in patients with regional stage, 38.3% (37.0%–
39.6%), and 15.9% (14.9%–17.0%) in patients with distant stage, and
55.2% (53.3%–57.1%), and 35.1% (33.1%–37.0%) in patients with missing
stage. Net survival decreased as the age at diagnosis increased in all
stages, but the disadvantage in older patients was more evident in ad-
vanced cancers and for cancerwithmissing stage (Fig. 1, Supplementary
Table 2).
One-year net survival did not differ much by sex for localised stage
(Fig. 2). For regional stage, one-year net survival was similar across
sexes up to 80 years old, then females had better net survival than
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Fig. 1. Net survival for patients aged 55, 65, 75 and 85 years old over the first three years after diagnosis by stage at diagnosis (top panel) and one-and three-year net survival by age at
diagnosis and stage at diagnosis (bottom panel).
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65–85 years old had better survival than females. Females withmissing
stage had lower net survival than males. Māori with localised stage had
similar net survival than non-Māori regardless of the age at diagnosis.
For the other stages, Māori had poorer net survival than Non-Māori.
For regional and distant stages, net survival decreased as the depriva-
tion index increased, but the difference across deprivation index quin-
tiles was small, and similar over time. Net survival decreased as
comorbidity score increased for localised and regional cancers. How-
ever, patients with higher comorbidity level had better survival than
those with lower level for distant cancer. For missing stage, patients
with high comorbidity level had poorer survival than other patients
up to 70 years old. Afterwards, they had better net survival. Patients di-
agnosed with colon cancer after an emergency admission had poorer
net survival regardless of the stage or the age at diagnosis. The differ-
ence in one-year net survival between those who had an emergency
presentation and those who had not increased as age increased, except
for distant cancers for whom the reverse was observed. Similar results
are observed three years after diagnosis (Supplementary Fig. 1), with
a few exceptions. Māori with distant stage had slightly better three-
year net survival than non-Māori. Difference in net survival across co-
morbidity levels were more marked for localised and regional cancers
at three than at oneyear since diagnosis. Patientswithhigher comorbid-
ity level had poorer three-year net survival than others when cancer
was diagnosed at later stage. For missing stage, patients with higher co-
morbidity level had significantly poorer net survival than other but dif-
ferences disappeared after the age of 80.
To better understand the age difference in net survival, we looked at
the age pattern of excess mortality hazard over time (Fig. 3). For1046localised stage, the EMHwas low for all ages, with a slight disadvantage
for older patients during the first fifteen months after diagnosis. The
tendency was reversed afterwards. For regional stage, the excess mor-
tality in older patients was obvious during the first six months after di-
agnosis. Then, the EMH ratios were close to 1 for all ages. For distant
stage, older patients had higher excess mortality than younger patients
for eighteen months after diagnosis. Then, the curves converged for all
ages, and the EMH ratios were close to 1. For missing stage, the excess
in mortality in older patients was highest during the first year after di-
agnosis and persisted over entire follow-up for the oldest patients.
We tested themodification effect of factors on the relationship of age
at diagnosis with the EMH (Supplementary Table 3). For localised stage,
no factors modified the age pattern of the EMH. For regional stage, the
effect of age on the EMH was greater in patients diagnosed after an
emergency presentation than other patients, especially in the first
three months after diagnosis (Fig. 4A). For distant stage, patients who
were not diagnosed after an emergency presentation had higher EMH
ratios than those who had an emergency presentation, mainly in the
first six months (Fig. 4B). The EMH ratio reached 1 after the first year
for patients with an emergency presentation, and later for the other pa-
tients. Females had higher EMH ratios compared to males over the en-
tire follow-up time. However, the sex difference was greatest in the
first three months after diagnosis and decreased afterwards to become
negligible at three years (Fig. 4C). For missing stage, comorbidity level
modified considerably the effect of age on the EMH, with EMH ratios
of up to 10 for patients with 25th percentile comorbidity score. The
lower comorbidity score, the higher the EMH ratio, mainly in the first
six months after diagnosis and in patients older than 80 years old
(Fig. 4D).
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This study, for the first time, provides a comprehensive descrip-
tion of patient-related and clinical factors that influence the effect
of age at diagnosis on the excess mortality hazard in patients with1047colon cancer aged over 50 in New Zealand. The stage at diagnosis
and an emergency presentation at diagnosis modified the most the
age disparity in colon cancer survival, while comorbidity played little
role. About patient-related factors, sex was the sole factor that influ-
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Fig. 3. Excess mortality hazard for patients aged 55, 65, 75 and 85 years old (top panel), and excess mortality hazard ratio for patients aged 65, 75 and 85 years compared to patients aged
55 years old during the first three years since diagnosis by stage at diagnosis (bottom panel).
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than males.
The female advantage in colon cancer survival in patients aged
under 65 years old is congruent with findings from the EUROCARE
study [20]. In Finland, the absolute difference in one-year relative sur-
vival between the 45–59-year group and the 75-and-over group was
also higher in females compared to males with distant colon cancer
[21]. As suggested by others, the interaction between the age at diagno-
sis and sex indicates possible involvement of sex hormones [20]. How-
ever, the causal mechanism explaining this interaction and the reason
why this concerns only patients with distant cancer remain unclear
and deserve further investigation.
Weare not aware of other studies looking at the effect of ethnicity on
age disparities in colon cancer survival. One United States study showed
black patients with colorectal cancer had greater age disparity in five-
year net survival than white patients, mainly explained by poorer sur-
vival among black patients aged over 75 compared to white patients
[22]. Because the relationship between ethnicity and healthcare system
is complex and specific to each country's history, any comparisons
across countries are not relevant. While our study confirmed the nega-
tive effect of deprivation on colon cancer survival [23], we did not find
any evidence of its role in age disparities in colon cancer survival.
Comorbidity is highly prevalent in patients with colon cancer, espe-
cially in older patients, and may affect the likelihood to receive treat-
ment, and impact survival [24]. However, our results suggest that
comorbidity does not fully explain the age disparity in colon cancer sur-
vival. Indeed, for cancers with known stage, the effect of age on the ex-
cess hazard of death was the same across all comorbidity levels,
suggesting that comorbidity affects cancer management regardless of
the age at diagnosis. All aspects of comorbidity may not be well1048captured with hospitalisation data, especially when comorbidity did
not require hospitalisation. However, in New Zealand, the C3 index per-
formed slightly better than a comorbidity index based on pharmaceuti-
cal data, that identify patients who had drug prescription for diseases
irrespective ofwhether the patientwashospitalised or not [25]. A differ-
ence in treatment based on the chronological age or the existence of
other unmeasured factors may explain lower survival in older patients
without comorbidity. Indeed, comorbidity alone does not reflect the
overall fitness status of patients. As older patients are heterogeneous
in terms of health status and fitness, the comprehensive assessment of
common geriatric conditions including functional status, falls, cognition,
nutritional status, social support helps identifying patients who may
benefit themost from cancer treatment [26]. However, to date, such in-
formation is not currently available at population level.
Factors related to timeliness of cancer diagnosis— i.e., the stage at di-
agnosis andanemergencypresentation—greatly affected agedisparities
in colon cancer survival, reflecting the effect of cancer management on
survival. The treatment phase is a critical period where age inequalities
occur [27], likely because physicians are lacking evidence-based treat-
ment strategies, especially in comorbid and oldest patients [8]. Surgery
is the standard treatment in early-stage colon cancers, but older patients
have a reduced likelihood of undergoing surgery [28]. They also experi-
enced higher post-operative mortality rates [29]. In New Zealand, the
percentage of death within 90 days of resection was 7.3% in patients
aged over 75, and 4.8% after elective resection against 1.5–2.9% and
0.0–1.7%, respectively, in younger patients [29]. InNewZealand, patients
over 75 years old were nine-times less likely to receive chemotherapy
than those aged 25–54 years old [30]. Yet, evidence suggests that fit
older patients may benefit from the same regimen of chemotherapy as
middle-aged patients [31], and less intensive therapies may be used in
S. Pilleron, C. Maringe, H. Charvat et al. Journal of Geriatric Oncology 12 (2021) 1044–1051unfit older patients [32]. The current New Zealand guidelines for non-
metastatic colon cancer management do not include recommendations
regarding chemotherapy or surgery tailored to older patients [33]. Yet,
without appropriate stratification, older patients are more likely to re-
ceive suboptimal treatment compared to middle-aged patients. Further
observational studies to investigate how treatment may influence age1049disparities in colon cancer survival at population-level are needed. How-
ever, these studies should be properly designed to remove the risk of
immortal-time bias, arising when the time of treatment initiation does
not coincide with time of cancer diagnosis [34].
Consistentlywith previous studies [10],we showed that older adults
were more prone to be diagnosed through emergency settings than
S. Pilleron, C. Maringe, H. Charvat et al. Journal of Geriatric Oncology 12 (2021) 1044–1051middle-aged patients. A diagnosis following an emergency presentation
was associatedwith a lower chance of curative treatment and an excess
risk of mortality, particularly in the initial months after diagnosis [10].
This is consistent with many other studies which have demonstrated
consistently poorer outcomes in people diagnosed as an emergency,
as well as older people beingmore likely to present urgently [10]. Emer-
gency surgery is challenging but outcomes have been shown to be bet-
ter in the hands of specialist, rather than generalist, surgeons [35] and in
older patients full geriatric assessment and multidisciplinary manage-
ment improves care [36]. Given screening programmes often only in-
clude people up to the age of 75 their ability to reduce emergency
presentation rates in the oldest populations is limited and so focussing
on optimising care for such cases is important if outcomes are to be im-
proved in older adults.
Because of the high risk of poor outcomes related to treatment in
older patients, effort should bemade on reducing delays in colon cancer
diagnosis. The roll-out of the national colorectal cancer screening pro-
gram began in 2017. Evidence suggests that colorectal cancer screening
program decreased the risk of an emergency admission to hospital prior
to a colorectal cancer diagnosis in adults targeted by screening program
[37], however, this positive effect may not be observed in older adults.
Besides, colon cancer symptoms, including abdominal pain, diarrhoea,
and constipation, have low specificity [38] and are prevalent in older pa-
tients, especially in individuals with other comorbid conditions. While
there was no publicly funded campaign of awareness of colon cancer
symptoms during the study period, the colorectal cancer screening pro-
gram launched in 2017 undoubtedly increase awareness of colorectal
cancer. At the patient level, presence of comorbidity increased the like-
lihood to be diagnosed with distant colorectal cancer in New Zealand
[39]. However, tumour stage was not correlated with the delay from
the onset of symptoms to the administration of definite treatment
[40]. Still, the potential effect of age was not analysed, and the audit
was restricted to one hospital only [40]. It is also possible that older peo-
ple are more likely to face barriers to timely accessing health care be-
cause of socio-economic factors [41]. A comprehensive understanding
of factors influencing timely diagnosis of colon cancer in older adults
is warranted in New Zealand to develop interventions to improve ear-
lier cancer diagnosis, regardless of age, that will ultimately reduce age
disparities observed at the population level.
Our study has limitations. The estimation of net survival relies on the
background mortality rates obtained from lifetables, and implies that
onematches patients with cancer to individuals from the general popu-
lation that should ideally present the same characteristics (sex, age,
socio-economic level, etc.) as patients except for cancer.When one is in-
terested in the effect of age on cancer survival, characteristics, such as
comorbidity, that influences both background mortality and cancer
mortality, have their importance, but are unavailable at population
level. Consequently, the estimation of excess mortality hazards may be
overestimated, and therefore our net survival estimates underestimated
[42]. Additionally, we acknowledge that age disparities in colon cancer
survival may differ depending on other unstudied factors such as
those related to the tumour (e.g. histology or the number of positive
lymph nodes involved) [11], or to access to health care system, or
more importantly, those influencing the receipt of treatment (e.g.
frailty, functional status, nutritional status, specific comorbidity, etc.).
However, in the present study, we restricted the number of variables in-
vestigated because of the relatively low number of cases by stage. An-
other essential aspect is patients' preference about treatment,
particularly important to consider as they age. Unfortunately, this as-
pect is difficult, even impossible, to capture using observational data.
Another limitation relies on the lack of validation of the definition we
use for an emergency presentation at diagnosis in the New Zealand set-
ting. However, the definition being based on the existence of hospital
records only, and not on clinical coding, the Elliss-Brooke et al. defini-
tion should perform well. This should be, however, investigated in fu-
ture studies. Finally, studied factors may have different effects on age1050disparities in cancer survival in other high-income countries because
of differences in the health-care system. Similar studies in other coun-
tries would be interesting to test the generalizability of our findings.
5. Conclusion
The present population-based study shows that factors reflecting
timeliness of cancer diagnosis affected the most the age difference in
colon cancer survival, probably due to their impact on treatment strat-
egy. In contrast, comorbidity and patient-related factors play a negligi-
ble role. It is Utopian to believe that colon cancer survival in older
patientsmay equal that inmiddle-aged patients. However, there are op-
portunities for enhancement, notably in improving earlier diagnosis in
older adults. Efforts towards this goal are likely to help reduce age dis-
parities in colon cancer survival in New Zealand.
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